https://www.thebodypro.com/category/raltegravir-isentress-mk0518

Raltegravir (Isentress)

The Latest

pregnant woman talking to doctor
Conference Coverage

Raltegravir Not Linked to Birth Defects, Study Shows

Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.

Pair of female feet on a bathroom scale
Conference Coverage

One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?

The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.

pregnant stomach
News

This Week in HIV Research: Pregnancy Findings That Aren't About Dolutegravir

Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors Img
Neurocognitive

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review Img

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

Promo Image
News

This Week in HIV Research: This Is Your Brain on Stigma

The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.

Chewable Raltegravir Tablets Can Be Crushed and Dispersed in Liquid for Young Children Img
Children (Ages 0-17)

Chewable Raltegravir Tablets Can Be Crushed and Dispersed in Liquid for Young Children

Chewable raltegravir tablets can be crushed and stirred until dispersed in water, apple juice or breast milk and given to younger children according to WHO weight bands.

Isentress HD in Clinical Trials Img

Isentress HD in Clinical Trials

Analyzing the data after one year, researchers found that the new formulation of raltegravir (Isentress HD) was roughly equivalent in effectiveness and safety to the older formulation.

Isentress HD: A New Once-Daily Formulation of Raltegravir Approved in Canada Img

Isentress HD: A New Once-Daily Formulation of Raltegravir Approved in Canada

In late June 2017, Health Canada licensed the sale and use of a new formulation of the anti-HIV drug raltegravir (Isentress) as part of the treatment of HIV.

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Raltegravir Pharmacokinetic Targets Met in High-Risk HIV-Exposed Infants

Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.